Global Patent Index - EP 3140426 A4

EP 3140426 A4 20180221 - BIOMARKERS AND METHODS FOR DIAGNOSIS OF EARLY STAGE PANCREATIC DUCTAL ADENOCARCINOMA

Title (en)

BIOMARKERS AND METHODS FOR DIAGNOSIS OF EARLY STAGE PANCREATIC DUCTAL ADENOCARCINOMA

Title (de)

BIOMARKER UND VERFAHREN ZUR DIAGNOSE VON DUKTALEM PANKREASADENOKARZINOM IM FRÜHSTADIUM

Title (fr)

BIOMARQUEURS ET PROCÉDÉS DE DIAGNOSTIC D'UN STADE PRÉCOCE DE L'ADÉNOCARCINOME CANALAIRE PANCRÉATIQUE

Publication

EP 3140426 A4 20180221 (EN)

Application

EP 15789055 A 20150506

Priority

  • US 201461990029 P 20140507
  • US 2015029429 W 20150506

Abstract (en)

[origin: WO2015171736A2] The present invention provides biomarker compositions and methods for the diagnosis and prognosis of PDAC. In a particular embodiment, the invention provides methods and compositions for screening, diagnosis and prognosis of early stage, asymptomatic PDAC.

IPC 8 full level

C12Q 1/68 (2018.01); C40B 30/04 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01)

CPC (source: EP US)

G01N 33/57438 (2013.01 - EP US); G01N 33/57488 (2013.01 - US); C12N 15/113 (2013.01 - US); G01N 2800/52 (2013.01 - US); G01N 2800/56 (2013.01 - US); G01N 2800/60 (2013.01 - US)

Citation (search report)

  • [X] US 2010092476 A1 20100415 - HANASH SAMIR M [US], et al
  • [X] WO 2006017573 A2 20060216 - BAUER A ROBERT JR [US]
  • [X] WO 03093443 A2 20031113 - RAVEN BIOTECHNOLOGIES INC [US], et al
  • [XI] XIN HONG ET AL: "ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer", JOURNAL OF SURGICAL ONCOLOGY, vol. 101, no. 7, 1 April 2010 (2010-04-01), US, pages 564 - 569, XP055360403, ISSN: 0022-4790, DOI: 10.1002/jso.21538
  • [XI] MICHAEL TACHEZY ET AL: "ALCAM (CD166) Expression and Serum Levels in Pancreatic Cancer", PLOS ONE, vol. 7, no. 6, 20 June 2012 (2012-06-20), pages e39018, XP055413452, DOI: 10.1371/journal.pone.0039018
  • [X] C KAHLERT ET AL: "Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse", BRITISH JOURNAL OF CANCER, vol. 101, no. 3, 14 July 2009 (2009-07-14), GB, pages 457 - 464, XP055413455, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6605136
  • [X] VASSILIS AGGELIS ET AL: "Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model", PROTEOMICS, vol. 9, no. 8, 31 March 2009 (2009-03-31), DE, pages 2118 - 2130, XP055413458, ISSN: 1615-9853, DOI: 10.1002/pmic.200800756
  • [X] DOOLEY S ET AL: "Hepatocyte-Specific Smad7 Expression Attenuates TGF-@b-Mediated Fibrogenesis and Protects Against Liver Damage", GASTROENTEROLOGY, ELSEVIER, US, vol. 135, no. 2, 15 May 2008 (2008-05-15), pages 642 - 659.e46, XP023901369, ISSN: 0016-5085, [retrieved on 20080801], DOI: 10.1053/J.GASTRO.2008.04.038
  • [X] CHAO NI ET AL: "Prognostic Value of CD166 Expression in Cancers of the Digestive System: A Systematic Review and Meta-Analysis", PLOS ONE, vol. 8, no. 8, 5 August 2013 (2013-08-05), pages e70958, XP055413465, DOI: 10.1371/journal.pone.0070958
  • See references of WO 2015171736A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2015171736 A2 20151112; WO 2015171736 A3 20160407; EP 3140426 A2 20170315; EP 3140426 A4 20180221; US 10451628 B2 20191022; US 11079384 B2 20210803; US 2017108502 A1 20170420; US 2020088733 A1 20200319; US 2021356469 A1 20211118

DOCDB simple family (application)

US 2015029429 W 20150506; EP 15789055 A 20150506; US 201515308579 A 20150506; US 201916658937 A 20191021; US 202117392051 A 20210802